Australia Allows Industry Collaboration To Continue
GBMA And Medicines Australia Get One-Year Extension From ACCC
Executive Summary
Australia’s competition authority has extended the arrangements allowing local off-patent industry body the GBMA to closely collaborate with brand organization Medicines Australia to co-ordinate supply against the backdrop of the ongoing COVID-19 pandemic.
You may also be interested in...
Covid-19: Australian Competition Body Confirms Industry Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.
Australian Body Confirms Collaboration Conditions
A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.
Australia's Competition Regulator Authorizes Another Year Of Close Collaboration
Australian off-patent industry association GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the Australian Competition and Consumer Commission has decided, extending an existing authorization by a further year.